Related Experiment Video
Updated: Sep 23, 2025
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task
S Gauthier1, A Boxer, D Knopman
1Serge Gauthier, McGill Center for Studies in Aging, Montreal, Canada, serge.gauthier@mcgill.ca.
Abstract:
There was consensus that both amyloid and tau pathologies should be targeted in Alzheimer's disease, as well as additional pathophysiological mechanisms such as neuroinflammation. The selection of one or both of these targets may depend upon a personalized approach that takes into account the genetic and acquired factors that cause AD in any given person as well as their stage of disease as reflected in a biomarker profile. The validation of this therapeutic approach will be made possible by new methodologies for subdividing into predominant pathology, by efficient methods for identifying people in the earliest stages of disease, and by combination studies.
Insights
Targeting amyloid and tau pathologies, alongside neuroinflammation, is crucial for Alzheimer's disease (AD) treatment. Personalized approaches considering genetics, acquired factors, and disease stage via biomarkers will guide effective therapeutic strategies.
Area of Science:
- Neuroscience
- Pathology
- Pharmacology
Background:
- Alzheimer's disease (AD) is characterized by complex pathologies, including amyloid plaques and tau tangles.
- Neuroinflammation is increasingly recognized as a significant contributor to AD pathogenesis.
- Current therapeutic strategies often focus on single targets, potentially limiting efficacy.
Purpose of the Study:
- To establish consensus on targeting multiple pathophysiological mechanisms in Alzheimer's disease.
- To explore the role of personalized medicine in selecting therapeutic targets for AD.
- To identify key advancements needed for validating combination therapeutic approaches.
Main Methods:
- Review and consensus-building among experts in Alzheimer's disease research.
- Analysis of genetic and acquired factors contributing to AD.
- Evaluation of biomarker profiles for disease staging.
Main Results:
- Consensus reached on targeting both amyloid and tau pathologies, as well as neuroinflammation.
- Personalized therapeutic selection based on individual factors and disease stage is recommended.
- Biomarker profiles are essential for identifying disease stage and guiding treatment.
Conclusions:
- A multi-target therapeutic approach, including amyloid, tau, and neuroinflammation, is advocated for Alzheimer's disease.
- Personalized medicine, informed by genetic, acquired, and biomarker data, is key to effective AD treatment.
- Advancements in pathology subtyping, early detection, and combination studies are critical for validating these approaches.
More Related Videos
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists